Agave-Laurate-Bioconjugated Fructans 降低高胰岛素血和胰岛素耐药性,同时增加IL-10在由高脂肪饮食诱导的代谢综合征的老鼠中
Angélica Sofía González-Garibay1,2, Georgina Sandoval1, Omar Ricardo Torres-González1
1Medical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C. (CIATEJ), Av. Normalistas No. 800 Col. Colinas de la Normal, Guadalajara C.P. 44270, Jalisco, Mexico.
Pharmaceuticals (Basel, Switzerland)
|August 29, 2024
概括
酸-生物结合的果通过减少肥胖和改善胰岛素抵抗,有效地控制了大鼠的代谢综合征 (MetS). 这种饮食干预也调节了炎症性细胞因子,显示出治疗代谢障碍的前景.
科学领域:
- 生物化学 生物化学
- 营养科学 营养科学
- 代谢研究研究 代谢研究
背景情况:
- 代谢综合征 (MetS) 是一种复杂的疾病,其特点是肥胖,高三糖血,高血压和胰岛素抵抗.
- 现有的MetS治疗方法往往存在局限性,需要探索新型治疗剂.
- 了解饮食成分对炎症途径的影响对于管理MetS至关重要.
研究的目的:
- 为了研究劳拉酸-生物结合的果在MetS.的老鼠模型中对亲和抗炎细胞因子的影响.
- 评估劳拉酸-生物结合的果酸素在改善与MetS相关的代谢功能障碍方面的治疗潜力.
- 评估劳拉酸 - 生物结合果对关键动物学和代谢参数的影响与MetS.相关.
主要方法:
- 在使用高脂肪饮食 (HFD) 的Wistar大鼠中诱导了MetS.
- 鼠被用劳拉特生物结合的果实素 (130毫克/公斤) 治疗,用于预防 (FL PREV) 或治疗 (FL REV).
- 测量了动物学参数 (体重,BMI,腹周),脂肪组织,血清脂质,葡萄糖,胰岛素和炎症标志物 (C反应蛋白,IL-10).
主要成果:
- 酸与生物结合的果显著减少了食物摄入量,体重,BMI,腹周和脂肪组织积累.
- 治疗导致血清甘油三,胰岛素水平,胰岛素耐药性和C-反应性蛋白降低.
- 观察到血清IL-10蛋白水平和mRNA表达的显著增加,表明具有抗炎作用.
结论:
- 劳拉酸盐-生物结合的果显示出作为治疗肥胖及其并发症的治疗药物具有显著的潜力.
- 这项研究支持使用酸与生物结合的果来改善胰岛素抵抗和2型糖尿病.
- 这些发现突显了酸与生物结合的果在改善代谢综合征和相关代谢功能障碍方面的有效性.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Overview of Carbohydrate Metabolism
809
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
809
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178


